Učitavanje...
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
Tanespimycin, a heat shock protein 90 (HSP90) inhibitor, induces apoptosis in drug-sensitive and -resistant MM cell lines and in tumour cells from patients with relapsed MM. In this phase 1 dose-escalation study, the safety, plasma pharmacokinetics, and biological/antitumour activity of tanespimycin...
Spremljeno u:
| Glavni autori: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2010
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3126095/ https://ncbi.nlm.nih.gov/pubmed/20618337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08265.x |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|